Armin Hofmeister
Inventor
Stats
- 38 US patents issued
- 58 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 38 US Patents Issued
- 58 US Applications Filed
- 347 Total Citation Count
- Dec 7, 2023 Most Recent Filing
- Sep 5, 2000 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| AVENTIS PHARMA DEUTSCHLAND GMBH | 1
| 2002
|
| SANOFI-AVENTIS DEUTSCHLAND GMBH | 2
4 4 6 10 10 8 2 3 3 | 2000
2001 2002 2003 2004 2006 2007 2008 2009 2010 |
| SANOFI-AVENTIS | 1
| 2008
|
| AVENTIS PHARMA S.A. | 1
| 2006
|
| SANOFI | 8
4 11 5 4 2 1 | 2007
2008 2009 2011 2012 2014 2015 |
Inventor Addresses
| Address | Duration |
|---|---|
| Dexheim, DE | Jun 21, 07 - May 13, 14 |
| Frankfurt Am Main, DE | Jul 30, 09 - Jul 30, 09 |
| Frankfurt am Main, DE | Sep 25, 08 - Nov 14, 24 |
| Frankfurt, DE | Oct 02, 08 - Aug 05, 14 |
| Frankurt am Main, DE | Apr 17, 08 - Dec 28, 10 |
| Kriftel, DE | Jan 08, 04 - May 23, 06 |
| Nierstein, DE | Jan 15, 02 - Sep 15, 09 |
| Oppenheim, DE | Sep 11, 03 - Nov 29, 11 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 51 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 24 |
| C07C: | ACYCLIC OR CARBOCYCLIC COMPOUNDS | 1 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 2024/0376,137 | 2024 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | 0 |
| 2024/0092,819 | 2024 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | 0 |
| 11897911 | 2024 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | 0 |
| 2024/0035,029 | 2024 | RNA COMPOSITIONS AND METHODS FOR INHIBITING LIPOPROTEIN(A) | 0 |
| 2023/0383,294 | 2023 | NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.